BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

...identified for which the standard of care doomed patients to a years-long, generally fruitless diagnostic odyssey...
BioCentury | May 4, 2018
Company News

Praluent gains exclusive status in exchange for lower net price

...for a lower price based on two pieces of new evidence: the results from the ODYSSEY...
...give Praluent exclusive status “took the combination of a better price and better data.” In ODYSSEY...
...the rebate it receives to patients and two-thirds to plan sponsors, Miller told BioCentury. In ODYSSEY...
BioCentury | May 1, 2018
Company News

Praluent gains exclusive status in exchange for lower net price

...for a lower price based on two pieces of new evidence: the results from the ODYSSEY...
...give Praluent exclusive status “took the combination of a better price and better data.” In ODYSSEY...
...the rebate it receives to patients and two-thirds to plan sponsors, Miller told BioCentury. In ODYSSEY...
BioCentury | Mar 23, 2018
Strategy

Arbiter of value

...of their PCSK9 inhibitor Praluent alirocumab carried out prior to publication of results from the ODYSSEY...
...the launch as “responsible” and immediately included Dupixent on the National Preferred Formulary. Similarly, when ODYSSEY...
...to say about value.” Leonard Schleifer, Regeneron Pearson told BioCentury the prespecified subgroup analysis in ODYSSEY...
BioCentury | Mar 23, 2018
Company News

Amgen examines barriers to PCSK9 inhibitor access

...NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data earlier this month from the Phase III ODYSSEY...
BioCentury | Mar 16, 2018
Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

...Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY...
...President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY...
...According to Sanofi, about one-third of patients in the trial met this criterion. Patients in ODYSSEY...
BioCentury | Mar 10, 2018
Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

...President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY...
...According to Sanofi, about one-third of patients in the trial met this criterion. Patients in ODYSSEY...
...mg/dL despite intensive statin therapy. The companies worked with ICER to provide it with the ODYSSEY...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Reduce CV events in patients with dyslipidemia who have had acute coronary syndrome Ph III ODYSSEY...
BioCentury | Oct 12, 2017
Finance

IRDiRC dreams bigger

...should be a solvable problem, because it's a systems problem," Austin said. "The current diagnostic odyssey...
BioCentury | May 19, 2017
Strategy

Contracting 2.0

...Assume that the full analysis of Amgen’s FOURIER or Regeneron Pharmaceuticals Inc. / Sanofi ’s ODYSSEY...
Items per page:
1 - 10 of 101
BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

...identified for which the standard of care doomed patients to a years-long, generally fruitless diagnostic odyssey...
BioCentury | May 4, 2018
Company News

Praluent gains exclusive status in exchange for lower net price

...for a lower price based on two pieces of new evidence: the results from the ODYSSEY...
...give Praluent exclusive status “took the combination of a better price and better data.” In ODYSSEY...
...the rebate it receives to patients and two-thirds to plan sponsors, Miller told BioCentury. In ODYSSEY...
BioCentury | May 1, 2018
Company News

Praluent gains exclusive status in exchange for lower net price

...for a lower price based on two pieces of new evidence: the results from the ODYSSEY...
...give Praluent exclusive status “took the combination of a better price and better data.” In ODYSSEY...
...the rebate it receives to patients and two-thirds to plan sponsors, Miller told BioCentury. In ODYSSEY...
BioCentury | Mar 23, 2018
Strategy

Arbiter of value

...of their PCSK9 inhibitor Praluent alirocumab carried out prior to publication of results from the ODYSSEY...
...the launch as “responsible” and immediately included Dupixent on the National Preferred Formulary. Similarly, when ODYSSEY...
...to say about value.” Leonard Schleifer, Regeneron Pearson told BioCentury the prespecified subgroup analysis in ODYSSEY...
BioCentury | Mar 23, 2018
Company News

Amgen examines barriers to PCSK9 inhibitor access

...NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data earlier this month from the Phase III ODYSSEY...
BioCentury | Mar 16, 2018
Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

...Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY...
...President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY...
...According to Sanofi, about one-third of patients in the trial met this criterion. Patients in ODYSSEY...
BioCentury | Mar 10, 2018
Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

...President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY...
...According to Sanofi, about one-third of patients in the trial met this criterion. Patients in ODYSSEY...
...mg/dL despite intensive statin therapy. The companies worked with ICER to provide it with the ODYSSEY...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Reduce CV events in patients with dyslipidemia who have had acute coronary syndrome Ph III ODYSSEY...
BioCentury | Oct 12, 2017
Finance

IRDiRC dreams bigger

...should be a solvable problem, because it's a systems problem," Austin said. "The current diagnostic odyssey...
BioCentury | May 19, 2017
Strategy

Contracting 2.0

...Assume that the full analysis of Amgen’s FOURIER or Regeneron Pharmaceuticals Inc. / Sanofi ’s ODYSSEY...
Items per page:
1 - 10 of 101